NCT01535950 - Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Neovascular Age-elated Macular Degeneration (Wet AMD)Exudative Macular Degeneration

Interventions

DRUG

LFG316

DRUG

Placebo

Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.

Trial Locations (7)

29169

Novartis Investigative Site, West Columbia

76104

Novartis Investigative Site, Fort Worth

79606

Novartis Investigative Site, Abilene

90503

Novartis Investigative Site, Torrance

85704-5614

Novartis Investigative Site, Tucson

33912-7125

Novartis Investigative Site, Fort Myers

21237-4350

Novartis Investigative Site, Baltimore